{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T15:11:28Z","timestamp":1778857888350,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"DOI":"10.1007\/s13760-026-03082-0","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:24:55Z","timestamp":1778855095000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Therapeutic effects of cannabinoids on Parkinson\u2019s disease: an updated systematic review and meta-analysis of randomized controlled trials"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2571-3934","authenticated-orcid":false,"given":"Mark","family":"Messak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-7902-690X","authenticated-orcid":false,"given":"Ahmed","family":"Abdelmageed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Noureldeen","family":"Abbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1019-2925","authenticated-orcid":false,"given":"Youssef","family":"Mandour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7975-6479","authenticated-orcid":false,"given":"Ahmed","family":"Talkhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud Fadel","family":"Eltohami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dua\u2019a","family":"Kanaan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4779-4166","authenticated-orcid":false,"given":"Fawaz K.","family":"Alfahmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-8515-8723","authenticated-orcid":false,"given":"Habiba Tariq","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4170-7619","authenticated-orcid":false,"given":"Lara Hamzeh","family":"Hamzeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-8594-4063","authenticated-orcid":false,"given":"Lamees","family":"Taman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5363-6369","authenticated-orcid":false,"given":"Ahmed","family":"Negida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"3082_CR1","unstructured":"Kouli A, Torsney KM, Kuan W-L (2018) Parkinson\u2019s Disease: Etiology, Neuropathology, and Pathogenesis. Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects [Internet]. Codon Publications. https:\/\/10.15586\/codonpublications.parkinsonsdisease.2018.ch1"},{"issue":"Suppl 1","key":"3082_CR2","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1468-1331.2008.02056.x","volume":"15","author":"W Poewe","year":"2008","unstructured":"Poewe W (2008) Non-motor symptoms in Parkinson\u2019s disease. Eur J Neurol 15(Suppl 1):14\u201320. https:\/\/doi.org\/10.1111\/j.1468-1331.2008.02056.x","journal-title":"Eur J Neurol"},{"key":"3082_CR3","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3233\/JPD-150650","volume":"5","author":"H Zach","year":"2015","unstructured":"Zach H, Dirkx M, Bloem BR, Helmich RC (2015) The Clinical Evaluation of Parkinson\u2019s Tremor. J Parkinsons Dis 5:471\u2013474. https:\/\/doi.org\/10.3233\/JPD-150650","journal-title":"J Parkinsons Dis"},{"key":"3082_CR4","doi-asserted-by":"publisher","first-page":"1498756","DOI":"10.3389\/fnagi.2024.1498756","volume":"16","author":"Y Luo","year":"2025","unstructured":"Luo Y, Qiao L, Li M et al (2025) Global, regional, national epidemiology and trends of Parkinson\u2019s disease from 1990 to 2021: findings from the Global Burden of Disease Study 2021. Front Aging Neurosci 16:1498756. https:\/\/doi.org\/10.3389\/fnagi.2024.1498756","journal-title":"Front Aging Neurosci"},{"key":"3082_CR5","doi-asserted-by":"publisher","first-page":"e080952","DOI":"10.1136\/bmj-2024-080952","volume":"388","author":"D Su","year":"2025","unstructured":"Su D, Cui Y, He C et al (2025) Projections for prevalence of Parkinson\u2019s disease and its driving factors in 195 countries and territories to 2050: modelling study of Global Burden of Disease Study 2021. BMJ 388:e080952. https:\/\/doi.org\/10.1136\/bmj-2024-080952","journal-title":"BMJ"},{"issue":"Suppl 2","key":"3082_CR6","first-page":"S32","volume":"17","author":"CD Marsden","year":"1994","unstructured":"Marsden CD (1994) Problems with long-term levodopa therapy for Parkinson\u2019s disease. Clin Neuropharmacol 17(Suppl 2):S32\u201344","journal-title":"Clin Neuropharmacol"},{"key":"3082_CR7","unstructured":"Sheikh NK, Dua A (2023) Cannabinoids. StatPearls [Internet]. StatPearls Publishing"},{"key":"3082_CR8","doi-asserted-by":"publisher","unstructured":"Tadijan A, Vla\u0161i\u0107 I, Vlaini\u0107 J et al (2022) Intracellular Molecular Targets and Signaling Pathways Involved in Antioxidative and Neuroprotective Effects of Cannabinoids in Neurodegenerative Conditions. https:\/\/doi.org\/10.3390\/antiox11102049. Antioxidants 11:2049","DOI":"10.3390\/antiox11102049"},{"key":"3082_CR9","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2174\/138161208785740072","volume":"14","author":"M Di Filippo","year":"2008","unstructured":"Di Filippo M, Picconi B, Tozzi A et al (2008) The endocannabinoid system in Parkinson\u2019s disease. Curr Pharm Des 14:2337\u20132347. https:\/\/doi.org\/10.2174\/138161208785740072","journal-title":"Curr Pharm Des"},{"key":"3082_CR10","doi-asserted-by":"publisher","first-page":"832854","DOI":"10.3389\/fncel.2022.832854","volume":"16","author":"M Wang","year":"2022","unstructured":"Wang M, Liu H, Ma Z (2022) Roles of the Cannabinoid System in the Basal Ganglia in Parkinson\u2019s Disease. Front Cell Neurosci 16:832854. https:\/\/doi.org\/10.3389\/fncel.2022.832854","journal-title":"Front Cell Neurosci"},{"key":"3082_CR11","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1002\/glia.20983","volume":"58","author":"N Stella","year":"2010","unstructured":"Stella N (2010) Cannabinoid and cannabinoid-like receptors in microglia, astrocytes and astrocytomas. Glia 58:1017\u20131030. https:\/\/doi.org\/10.1002\/glia.20983","journal-title":"Glia"},{"key":"3082_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/ijms22010019","volume":"22","author":"JA Komorowska-M\u00fcller","year":"2021","unstructured":"Komorowska-M\u00fcller JA, Schm\u00f6le A-C (2021) CB2 Receptor in Microglia: The Guardian of Self-Control. Int J Mol Sci 22:19. https:\/\/doi.org\/10.3390\/ijms22010019","journal-title":"Int J Mol Sci"},{"key":"3082_CR13","doi-asserted-by":"crossref","unstructured":"Urbi B, Corbett J, Hughes I et al (2021) Effects of Cannabis in Parkinson\u2019s Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson\u2019s Disease","DOI":"10.3233\/JPD-212923"},{"key":"3082_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/00002826-200405000-00003","volume":"27","author":"V Mesnage","year":"2004","unstructured":"Mesnage V, Houeto JL, Bonnet AM et al (2004) Neurokinin B, Neurotensin, and Cannabinoid Receptor Antagonists and Parkinson Disease. Clin Neuropharmacol 27:108","journal-title":"Clin Neuropharmacol"},{"key":"3082_CR15","doi-asserted-by":"publisher","first-page":"175628642110185","DOI":"10.1177\/17562864211018561","volume":"14","author":"SJ Thanabalasingam","year":"2021","unstructured":"Thanabalasingam SJ, Ranjith B, Jackson R, Wijeratne DT (2021) Cannabis and its derivatives for the use of motor symptoms in Parkinson\u2019s disease: a systematic review and meta-analysis. Ther Adv Neurol Disord 14:17562864211018561. https:\/\/doi.org\/10.1177\/17562864211018561","journal-title":"Ther Adv Neurol Disord"},{"key":"3082_CR16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"3082_CR17","doi-asserted-by":"publisher","unstructured":"Higgins JPT, Thomas J, Chandler J et al (2019) Cochrane Handbook for Systematic Reviews of Interventions. https:\/\/doi.org\/10.1002\/9781119536604","DOI":"10.1002\/9781119536604"},{"key":"3082_CR18","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Reviews 5:210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Reviews"},{"key":"3082_CR19","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/9781119536604.ch8","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Savovi\u0107 J, Page MJ et al (2019) Assessing risk of bias in a randomized trial. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, Ltd, pp 205\u2013228"},{"key":"3082_CR20","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synthesis Methods 12:55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synthesis Methods"},{"key":"3082_CR21","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3082_CR22","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz CG, Tilley BC, Shaftman SR et al (2008) Movement Disorder Society-sponsored revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129\u20132170. https:\/\/doi.org\/10.1002\/mds.22340","journal-title":"Mov Disord"},{"key":"3082_CR23","doi-asserted-by":"publisher","first-page":"175628482110664","DOI":"10.1177\/17562848211066439","volume":"15","author":"A Avinir","year":"2022","unstructured":"Avinir A, Dar S, Taler M et al (2022) Keeping it simple: mental health assessment in the Gastroenterology Department \u2013 using the Hospital Anxiety and Depression Scale (HADS) for IBD patients in Israel. Th Adv Gastroenterol 15:17562848211066439. https:\/\/doi.org\/10.1177\/17562848211066439","journal-title":"Th Adv Gastroenterol"},{"key":"3082_CR24","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1002\/mdc3.12553","volume":"5","author":"SK Holden","year":"2017","unstructured":"Holden SK, Finseth T, Sillau SH, Berman BD (2017) Progression of MDS-UPDRS Scores Over Five Years in De Novo Parkinson Disease from the Parkinson\u2019s Progression Markers Initiative Cohort. Mov Disord Clin Pract 5:47\u201353. https:\/\/doi.org\/10.1002\/mdc3.12553","journal-title":"Mov Disord Clin Pract"},{"key":"3082_CR25","doi-asserted-by":"publisher","first-page":"e0266140","DOI":"10.1371\/journal.pone.0266140","volume":"17","author":"A Sch\u00f6nenberg","year":"2022","unstructured":"Sch\u00f6nenberg A, Prell T (2022) Measuring quality of life with the Parkinson\u2019s Disease Questionnaire-39 in people with cognitive impairment. PLoS ONE 17:e0266140. https:\/\/doi.org\/10.1371\/journal.pone.0266140","journal-title":"PLoS ONE"},{"key":"3082_CR26","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G (2019) How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health 22:153\u2013160. https:\/\/doi.org\/10.1136\/ebmental-2019-300117","journal-title":"Evid Based Ment Health"},{"key":"3082_CR27","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/9780470743386.ch4","volume-title":"Introduction to Meta-Analysis","author":"M Borenstein","year":"2009","unstructured":"Borenstein M, Hedges LV, Higgins JPT, Rothstein FHR (2009) Effect Sizes Based on Means. Introduction to Meta-Analysis. Wiley, Ltd, pp 21\u201332"},{"key":"3082_CR28","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/B978-0-08-057065-5.50010-5","volume-title":"Statistical Methods for Meta-Analysis","author":"LV Hedges","year":"1985","unstructured":"Hedges LV, Olkin I (1985) CHAPTER 5 - Estimation of a Single Effect Size: Parametric and Nonparametric Methods. In: Hedges LV, Olkin I (eds) Statistical Methods for Meta-Analysis. Academic, San Diego, pp 75\u2013106"},{"key":"3082_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/9781119536604.ch10","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JJ Deeks","year":"2019","unstructured":"Deeks JJ, Higgins JP, Altman DG, Group on behalf of the CSM (2019) Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, Ltd, pp 241\u2013284"},{"key":"3082_CR30","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1177\/0269881114550355","volume":"28","author":"MHN Chagas","year":"2014","unstructured":"Chagas MHN, Zuardi AW, Tumas V et al (2014) Effects of cannabidiol in the treatment of patients with Parkinson\u2019s disease: an exploratory double-blind trial. J Psychopharmacol 28:1088\u20131098. https:\/\/doi.org\/10.1177\/0269881114550355","journal-title":"J Psychopharmacol"},{"key":"3082_CR31","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/9781119536604.ch23","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Eldridge S, Li T (2019) Including variants on randomized trials. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, Ltd, pp 569\u2013593"},{"key":"3082_CR32","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/9781119536604.ch6","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"JP Higgins","year":"2019","unstructured":"Higgins JP, Li T, Deeks JJ (2019) Choosing effect measures and computing estimates of effect. Cochrane Handbook for Systematic Reviews of Interventions. Wiley, Ltd, pp 143\u2013176"},{"key":"3082_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/1471-2288-5-13","volume":"5","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 5:13. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"key":"3082_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/s12874-024-02356-6","volume":"24","author":"A Abbas","year":"2024","unstructured":"Abbas A, Hefnawy MT, Negida A (2024) Meta-analysis accelerator: a comprehensive tool for statistical data conversion in systematic reviews with meta-analysis. BMC Med Res Methodol 24:243. https:\/\/doi.org\/10.1186\/s12874-024-02356-6","journal-title":"BMC Med Res Methodol"},{"key":"3082_CR35","doi-asserted-by":"publisher","first-page":"663","DOI":"10.25259\/JNRP-2022-6-19","volume":"13","author":"A Kanjanarangsichai","year":"2022","unstructured":"Kanjanarangsichai A, Mitarnun W, Mitarnun W et al (2022) Cannabidiol-enriched cannabis extraction product in Parkinson\u2019s disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital. J Neurosci Rural Pract 13:663\u2013668. https:\/\/doi.org\/10.25259\/JNRP-2022-6-19","journal-title":"J Neurosci Rural Pract"},{"key":"3082_CR36","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/mds.29768","volume":"39","author":"Y Liu","year":"2024","unstructured":"Liu Y, Bainbridge J, Sillau S et al (2024) Short-Term Cannabidiol with \u2206-9-Tetrahydrocannabinol in Parkinson\u2019s Disease: A Randomized Trial. Mov Disord 39:863\u2013875. https:\/\/doi.org\/10.1002\/mds.29768","journal-title":"Mov Disord"},{"key":"3082_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.18637\/jss.v036.i03","volume":"36","author":"W Viechtbauer","year":"2010","unstructured":"Viechtbauer W (2010) Conducting Meta-Analyses in R with the metafor Package. J Stat Softw 36:1\u201348. https:\/\/doi.org\/10.18637\/jss.v036.i03","journal-title":"J Stat Softw"},{"key":"3082_CR38","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1002\/ana.25864","volume":"88","author":"M Peball","year":"2020","unstructured":"Peball M, Krismer F, Knaus H-G et al (2020) Non-Motor Symptoms in Parkinson\u2019s Disease are Reduced by Nabilone. Ann Neurol 88:712\u2013722. https:\/\/doi.org\/10.1002\/ana.25864","journal-title":"Ann Neurol"},{"key":"3082_CR39","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1212\/01.wnl.0000140288.48796.8e","volume":"63","author":"CB Carroll","year":"2004","unstructured":"Carroll CB, Bain PG, Teare L et al (2004) Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study. Neurology 63:1245\u20131250. https:\/\/doi.org\/10.1212\/01.wnl.0000140288.48796.8e","journal-title":"Neurology"},{"key":"3082_CR40","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1037\/1082-989X.7.1.105","volume":"7","author":"SB Morris","year":"2002","unstructured":"Morris SB, DeShon RP (2002) Combining effect size estimates in meta-analysis with repeated measures and independent-groups designs. Psychol Methods 7:105\u2013125. https:\/\/doi.org\/10.1037\/1082-989X.7.1.105","journal-title":"Psychol Methods"},{"key":"3082_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Smith GD, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315:629\u2013634. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"key":"3082_CR42","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1212\/wnl.57.11.2108","volume":"57","author":"KA Sieradzan","year":"2001","unstructured":"Sieradzan KA, Fox SH, Hill M et al (2001) Cannabinoids reduce levodopa-induced dyskinesia in Parkinson\u2019s disease: a pilot study. Neurology 57:2108\u20132111. https:\/\/doi.org\/10.1212\/wnl.57.11.2108","journal-title":"Neurology"},{"key":"3082_CR43","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1177\/0269881119895536","volume":"34","author":"SM de Faria","year":"2020","unstructured":"de Faria SM, de Morais Fabr\u00edcio D, Tumas V et al (2020) Effects of acute cannabidiol administration on anxiety and tremors induced by a Simulated Public Speaking Test in patients with Parkinson\u2019s disease. J Psychopharmacol 34:189\u2013196. https:\/\/doi.org\/10.1177\/0269881119895536","journal-title":"J Psychopharmacol"},{"key":"3082_CR44","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mdc3.13754","volume":"10","author":"DG Di Luca","year":"2023","unstructured":"Di Luca DG, Gilmour GS, Fearon C et al (2023) A Phase Ib, Double Blind, Randomized Study of Cannabis Oil for Pain in Parkinson\u2019s Disease. Mov Disord Clin Pract 10:1114\u20131119. https:\/\/doi.org\/10.1002\/mdc3.13754","journal-title":"Mov Disord Clin Pract"},{"key":"3082_CR45","doi-asserted-by":"publisher","unstructured":"Domen CH, Sillau S, Liu Y et al (2023) . Cognitive Safety Data from a Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase IIb Study of the Effects of a Cannabidiol and \u22069-Tetrahydrocannabinol Drug on Parkinson\u2019s Disease-Related Motor Symptoms. Mov Disord 38:1341\u20131346. https:\/\/doi.org\/10.1002\/mds.29447","DOI":"10.1002\/mds.29447"},{"key":"3082_CR46","doi-asserted-by":"publisher","first-page":"e49965","DOI":"10.2196\/49965","volume":"7","author":"I Weber","year":"2024","unstructured":"Weber I, Zagona-Prizio C, Sivesind TE et al (2024) Oral Cannabidiol for Seborrheic Dermatitis in Patients With Parkinson Disease: Randomized Clinical Trial. JMIR Dermatol 7:e49965. https:\/\/doi.org\/10.2196\/49965","journal-title":"JMIR Dermatol"},{"key":"3082_CR47","doi-asserted-by":"publisher","first-page":"107841","DOI":"10.1016\/j.parkreldis.2025.107841","volume":"135","author":"W Mitarnun","year":"2025","unstructured":"Mitarnun W, Kanjanarangsichai A, Junlaor P et al (2025) Cannabidiol and cognitive functions\/inflammatory markers in Parkinson\u2019s disease: A double-blind randomized controlled trial at Buriram Hospital (CBD-PD-BRH trial). Parkinsonism Relat Disord 135:107841. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107841","journal-title":"Parkinsonism Relat Disord"},{"key":"3082_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1146\/annurev-neuro-070815-014038","volume":"39","author":"NE Zlebnik","year":"2016","unstructured":"Zlebnik NE, Cheer JF (2016) Beyond the CB1 Receptor: Is Cannabidiol the Answer for Disorders of Motivation? Annu Rev Neurosci 39:1\u201317. https:\/\/doi.org\/10.1146\/annurev-neuro-070815-014038","journal-title":"Annu Rev Neurosci"},{"key":"3082_CR49","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.bbr.2013.03.015","volume":"247","author":"A Rashidy-Pour","year":"2013","unstructured":"Rashidy-Pour A, Pahlevani P, Vaziri A et al (2013) Involvement of CB1 receptors in the ventral tegmental area in the potentiation of morphine rewarding properties in acquisition but not expression in the conditioned place preference model. Behav Brain Res 247:259\u2013267. https:\/\/doi.org\/10.1016\/j.bbr.2013.03.015","journal-title":"Behav Brain Res"},{"key":"3082_CR50","doi-asserted-by":"publisher","unstructured":"Shahbazi-Raz F, Meister D, Mohammadzadeh A, Trant JF (2025) How THC works: Explaining ligand affinity for, and partial agonism of, cannabinoid receptor 1. iScience 28:112706. https:\/\/doi.org\/10.1016\/j.isci.2025.112706","DOI":"10.1016\/j.isci.2025.112706"},{"key":"3082_CR51","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.neuropharm.2017.04.033","volume":"124","author":"D Covey","year":"2017","unstructured":"Covey D, Mateo Y, Sulzer D et al (2017) Endocannabinoid modulation of dopamine neurotransmission. Neuropharmacology 124:52\u201361. https:\/\/doi.org\/10.1016\/j.neuropharm.2017.04.033","journal-title":"Neuropharmacology"},{"key":"3082_CR52","doi-asserted-by":"publisher","first-page":"e0220025","DOI":"10.1371\/journal.pone.0220025","volume":"14","author":"H Chung","year":"2019","unstructured":"Chung H, Fierro A, Pessoa-Mahana CD (2019) Cannabidiol binding and negative allosteric modulation at the cannabinoid type 1 receptor in the presence of delta-9-tetrahydrocannabinol: An In Silico study. PLoS ONE 14:e0220025. https:\/\/doi.org\/10.1371\/journal.pone.0220025","journal-title":"PLoS ONE"},{"key":"3082_CR53","unstructured":"Ng T, Gupta V, Keshock MC (2023) Tetrahydrocannabinol (THC). StatPearls [Internet]. StatPearls Publishing"},{"key":"3082_CR54","first-page":"482","volume":"115","author":"E Stuyt","year":"2018","unstructured":"Stuyt E (2018) The Problem with the Current High Potency THC Marijuana from the Perspective of an Addiction Psychiatrist. Mo Med 115:482\u2013486","journal-title":"Mo Med"},{"key":"3082_CR55","doi-asserted-by":"publisher","first-page":"116742","DOI":"10.1016\/j.bcp.2025.116742","volume":"233","author":"C Alexander","year":"2025","unstructured":"Alexander C, Jeon J, Nickerson K et al (2025) CBD and the 5-HT1A receptor: A medicinal and pharmacological review. Biochem Pharmacol 233:116742. https:\/\/doi.org\/10.1016\/j.bcp.2025.116742","journal-title":"Biochem Pharmacol"},{"key":"3082_CR56","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3389\/fnana.2020.00026","volume":"14","author":"A Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz A, Lopez-Lopez A, Labandeira CM, Labandeira-Garcia JL (2020) Interactions Between the Serotonergic and Other Neurotransmitter Systems in the Basal Ganglia: Role in Parkinson\u2019s Disease and Adverse Effects of L-DOPA. Front Neuroanat 14:26. https:\/\/doi.org\/10.3389\/fnana.2020.00026","journal-title":"Front Neuroanat"},{"key":"3082_CR57","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1007\/s11095-023-03469-1","volume":"40","author":"GTY Yau","year":"2023","unstructured":"Yau GTY, Tai W, Arnold JC et al (2023) Cannabidiol for the Treatment of Brain Disorders: Therapeutic Potential and Routes of Administration. Pharm Res 40:1087\u20131114. https:\/\/doi.org\/10.1007\/s11095-023-03469-1","journal-title":"Pharm Res"},{"key":"3082_CR58","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J (2018) The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 84:2477\u20132482. https:\/\/doi.org\/10.1111\/bcp.13710","journal-title":"Br J Clin Pharmacol"},{"key":"3082_CR59","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-020-00931-w","volume":"59","author":"V Franco","year":"2020","unstructured":"Franco V, Gershkovich P, Perucca E, Bialer M (2020) The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations. Clin Pharmacokinet 59:1493\u20131500. https:\/\/doi.org\/10.1007\/s40262-020-00931-w","journal-title":"Clin Pharmacokinet"},{"key":"3082_CR60","doi-asserted-by":"publisher","unstructured":"Nie Y, Kong Y, Peng J et al (2024) Enhanced oral bioavailability of cannabidiol by flexible zein nanoparticles: in vitro and pharmacokinetic studies. Front Nutr 11. https:\/\/doi.org\/10.3389\/fnut.2024.1431620","DOI":"10.3389\/fnut.2024.1431620"},{"key":"3082_CR61","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.3390\/brainsci11121573","volume":"11","author":"S Prakash","year":"2021","unstructured":"Prakash S, Carter WG (2021) The Neuroprotective Effects of Cannabis-Derived Phytocannabinoids and Resveratrol in Parkinson\u2019s Disease: A Systematic Literature Review of Pre-Clinical Studies. Brain Sci 11:1573. https:\/\/doi.org\/10.3390\/brainsci11121573","journal-title":"Brain Sci"},{"key":"3082_CR62","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/B978-0-12-800756-3.00099-5","volume-title":"Handbook of Cannabis and Related Pathologies","author":"RE Balter","year":"2017","unstructured":"Balter RE, Haney M (2017) The Synthetic Analog of \u22069-Tetrahydrocannabinol (THC): Nabilone. Pharmacology and Clinical Application. In: Preedy VR (ed) Handbook of Cannabis and Related Pathologies. Academic, San Diego, pp 821\u2013827"},{"key":"3082_CR63","doi-asserted-by":"crossref","unstructured":"Wallach J (2021) Medicinal Cannabis: an overview for health-care providers. In: Adejare A (ed) Remington (Twenty-third Edition). Academic, pp 75\u2013101","DOI":"10.1016\/B978-0-12-820007-0.00005-2"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03082-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03082-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03082-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:24:59Z","timestamp":1778855099000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-026-03082-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":63,"alternative-id":["3082"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03082-0","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"11 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors confirm that the content of this study has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate"}}]}}